NEW YORK – Bedminster, New Jersey-based Jubilant Therapeutics said on Thursday that it has identified potential indications and biomarkers of response for its investigational LSD1/HDAC6 inhibitor, called JBI-802, with the help of OneThree Biotech's artificial intelligence platform.